Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
US10195272B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Mar 29, 2016 |
| Grant date | Feb 5, 2019 |
| Priority date | — |
| Expiry date | Apr 20, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A chimeric antigen receptor (CAR) contains a human FcεRIα extracellular domain or a mutant FcεRIα extracellular domain that has a reduced binding affinity for human IgE compared to wild type human FcεRIα extracellular domain. The CAR further contains an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM). The CAR may further comprise a costimulatory signaling domain, such as an intracellular domain of at least one of the costimulatory molecules 4-1BB, CD27, CD28, CD134 or ICOS. T cells transduced with vectors encoding the CAR are used in CAR-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.